Phase II Trial of Erlotinib Plus Gemcitabine Chemotherapy in Korean Patients with Advanced Pancreatic Cancer and Prognostic Factors for Chemotherapeutic Response

BACKGROUND/AIMS: Erlotinib and gemcitabine combined chemotherapy is becoming the treatment of choice in advanced pancreatic cancer. We evaluated the effectiveness of treatment with erlotinib plus gemcitabine and the prognostic factors for chemotherapeutic response in Korean pancreatic cancer patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Semi, Chung, Moon Jae, Park, Jeong Youp, Chung, Jae Bock, Bang, Seungmin, Park, Seung Woo, Song, Si Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Gastroenterology; the Korean Society of Gastrointestinal Endoscopy; the Korean Association for the Study of the Liver; the Korean Society of Neurogastroenterology and Motility; Korean Association for the Study of Intestinal Diseases; Korean College of Helicobacter and Upper Gastrointestinal Research; Korean Pancreatobiliary Association; Korean Society of Gastrointestinal Cancer 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782678/
https://www.ncbi.nlm.nih.gov/pubmed/24073321
http://dx.doi.org/10.5009/gnl.2013.7.5.611

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782678/
https://www.ncbi.nlm.nih.gov/pubmed/24073321
http://dx.doi.org/10.5009/gnl.2013.7.5.611

Ejemplares similares